These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 30369576)

  • 21. Factors associated with non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with new-onset atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II).
    Steinberg BA; Shrader P; Thomas L; Ansell J; Fonarow GC; Gersh BJ; Hylek E; Kowey PR; Mahaffey KW; O'Brien EC; Singer DE; Peterson ED; Piccini JP;
    Am Heart J; 2017 Jul; 189():40-47. PubMed ID: 28625380
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Discontinuation rates of warfarin versus direct acting oral anticoagulants in US clinical practice: Results from Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II).
    Jackson LR; Kim S; Blanco R; Thomas L; Ansell J; Fonarow GC; Gersh BJ; Go AS; Kowey PR; Mahaffey KW; Hylek EM; Peterson ED; Piccini JP;
    Am Heart J; 2020 Aug; 226():85-93. PubMed ID: 32526533
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Patient-Reported Treatment Satisfaction with Rivaroxaban for Stroke Prevention in Atrial Fibrillation. A French Observational Study, the SAFARI Study.
    Hanon O; Chaussade E; Gueranger P; Gruson E; Bonan S; Gay A
    PLoS One; 2016; 11(12):e0166218. PubMed ID: 27935987
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Three-month risk-benefit profile of anticoagulation after stroke with atrial fibrillation: The SAMURAI-Nonvalvular Atrial Fibrillation (NVAF) study.
    Arihiro S; Todo K; Koga M; Furui E; Kinoshita N; Kimura K; Yamagami H; Terasaki T; Yoshimura S; Shiokawa Y; Kamiyama K; Takizawa S; Okuda S; Okada Y; Nagakane Y; Kameda T; Hasegawa Y; Shibuya S; Ito Y; Nakashima T; Takamatsu K; Nishiyama K; Matsuki T; Homma K; Takasugi J; Tokunaga K; Sato S; Kario K; Kitazono T; Toyoda K;
    Int J Stroke; 2016 Jul; 11(5):565-74. PubMed ID: 26927811
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparative effectiveness and safety of oral anticoagulants for atrial fibrillation in real-world practice: a population-based cohort study protocol.
    Holbrook A; Dormuth C; Morrow R; Lee A; Troyan S; Li G; Pullenyegum E
    BMJ Open; 2016 Nov; 6(11):e013263. PubMed ID: 27884850
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Patient-reported treatment satisfaction and budget impact with rivaroxaban vs. standard therapy in elective cardioversion of atrial fibrillation: a post hoc analysis of the X-VeRT trial.
    Hohnloser SH; Cappato R; Ezekowitz MD; Evers T; Sahin K; Kirchhof P; Meng IL; van Eickels M; Camm AJ;
    Europace; 2016 Feb; 18(2):184-90. PubMed ID: 26487668
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The anti-clot treatment scale (ACTS): validation of the translated Arabic version among patients undergoing warfarin therapy in Saudi Arabia.
    Shilbayeh SAR; Ibrahim AA
    Health Qual Life Outcomes; 2020 Jul; 18(1):215. PubMed ID: 32631346
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Tasmanian atrial fibrillation study: Transition to direct oral anticoagulants 2011-2015.
    Alamneh EA; Chalmers L; Bereznicki LR
    Cardiovasc Ther; 2017 Jun; 35(3):. PubMed ID: 28177198
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prevention of stroke in patients with atrial fibrillation.
    Olsson SB; Halperin JL
    Semin Vasc Med; 2005 Aug; 5(3):285-92. PubMed ID: 16123916
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Different determinants of vascular and nonvascular deaths in patients with atrial fibrillation: A SAKURA AF Registry substudy.
    Kuronuma K; Okumura Y; Yokoyama K; Matsumoto N; Tachibana E; Oiwa K; Matsumoto M; Kojima T; Hanada S; Nomoto K; Arima K; Takahashi F; Kotani T; Ikeya Y; Fukushima S; Itou S; Kondo K; Chiku M; Ohno Y; Onikura M; Hirayama A;
    J Cardiol; 2019 Mar; 73(3):210-217. PubMed ID: 30591323
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Differences in knowledge among patients with atrial fibrillation receiving non-vitamin K antagonist oral anticoagulants and vitamin K antagonists.
    Konieczyńska M; Sobieraj E; Bryk AH; Dębski M; Polak M; Podolec P; Małecka B; Pająk A; Desteghe L; Heidbuchel H; Undas A
    Kardiol Pol; 2018; 76(7):1089-1096. PubMed ID: 29528483
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical Characteristics, Oral Anticoagulation Patterns, and Outcomes of Medicaid Patients With Atrial Fibrillation: Insights From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF I) Registry.
    O'Brien EC; Kim S; Thomas L; Fonarow GC; Kowey PR; Mahaffey KW; Gersh BJ; Piccini JP; Peterson ED
    J Am Heart Assoc; 2016 May; 5(5):. PubMed ID: 27146448
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost Effectiveness of Apixaban versus Warfarin or Aspirin for Stroke Prevention in Patients with Atrial Fibrillation: A Greek Perspective.
    Athanasakis K; Boubouchairopoulou N; Karampli E; Tarantilis F; Savvari P; Bilitou A; Kyriopoulos J
    Am J Cardiovasc Drugs; 2017 Apr; 17(2):123-133. PubMed ID: 27882517
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Patient satisfaction with warfarin- and non-warfarin-containing thromboprophylaxis regimens for atrial fibrillation.
    Coleman CI; Coleman SM; Vanderpoel J; Nelson W; Colby JA; Scholle JM; Kluger J
    J Investig Med; 2013 Jun; 61(5):878-81. PubMed ID: 23524987
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Physical, cognitive, and psychosocial conditions in relation to anticoagulation satisfaction among elderly adults with atrial fibrillation: The SAGE-AF study.
    Wang W; Saczynski J; Lessard D; Mailhot T; Barton B; Waring ME; Sogade F; Hayward R; Helm R; McManus DD
    J Cardiovasc Electrophysiol; 2019 Nov; 30(11):2508-2515. PubMed ID: 31515920
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Assessment of Patient Adherence to Direct Oral Anticoagulant vs Warfarin Therapy.
    Patel SI; Cherington C; Scherber R; Barr K; McLemore R; Morisky DE; Cha S; Mookadam F; Shamoun F
    J Am Osteopath Assoc; 2017 Jan; 117(1):7-15. PubMed ID: 28055097
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Suboptimal Anticoagulant Management in Japanese Patients with Nonvalvular Atrial Fibrillation Receiving Warfarin for Stroke Prevention.
    Hirano T; Kaneko H; Mishina S; Wang F; Morita S
    J Stroke Cerebrovasc Dis; 2017 Oct; 26(10):2102-2110. PubMed ID: 28532651
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inadequate stroke prevention in Korean atrial fibrillation patients in the post-warfarin era.
    Choi EJ; Lee IH; Je NK
    Int J Cardiol; 2016 Oct; 220():647-52. PubMed ID: 27393842
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of Treatment Persistence with Dabigatran or Rivaroxaban versus Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation Patients: A Competing Risk Analysis in the French National Health Care Databases.
    Maura G; Billionnet C; Alla F; Gagne JJ; Pariente A
    Pharmacotherapy; 2018 Jan; 38(1):6-18. PubMed ID: 29028119
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Real-World Adherence and Persistence with Direct Oral Anticoagulants in Adults with Atrial Fibrillation.
    Manzoor BS; Lee TA; Sharp LK; Walton SM; Galanter WL; Nutescu EA
    Pharmacotherapy; 2017 Oct; 37(10):1221-1230. PubMed ID: 28730619
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.